Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER1 | P34995 | 14/20 | 0.63 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.63 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.63 |
| ▸ | PPIA | P62937 | 2/20 | 0.52 |
| ▸ | NPC1 | O15118 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.47 |
| ▸ | PTGER4 | P35408 | 3/20 | 0.46 |
| ▸ | PTGER3 | P43115 | 3/20 | 0.46 |
| ▸ | PTGER2 | P43116 | 3/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4882669 | 0.90 | PTGER1 (0.80) | PTGER1CYP2C9CYP3A4 | |
| SCHEMBL5110014 | 0.90 | PTGER1 (0.74) | PTGER1CYP2C9PPIANPC1ALDH1A1 | |
| SCHEMBL4886674 | 0.88 | PTGER1 (0.79) | PTGER1CYP2C9CYP3A4PTGER4PTGER3 | |
| SCHEMBL14028923 | 0.87 | PTGER1 (0.47) | PTGER1CYP2C9CYP3A4NPC1RAB9A | |
| SCHEMBL4884294 | 0.86 | PTGER1 (0.80) | PTGER1CYP2C9CYP3A4 | |
| SCHEMBL4884412 | 0.85 | PTGER1 (0.56) | PTGER1CYP2C9CYP3A4PPIAALDH1A1 | |
| SCHEMBL5102961 | 0.83 | PTGER1 (0.57) | PTGER1CYP2C9CYP3A4PPIA | |
| SCHEMBL5099258 | 0.80 | PTGER1 (0.77) | PTGER1CYP2C9CYP3A4 | |
| SCHEMBL6684764 | 0.78 | PTGER1 (0.52) | PTGER1CYP2C9PPIANPC1ALDH1A1 | |
| SCHEMBL5096018 | 0.78 | PTGER1 (0.54) | PTGER1CYP2C9CYP3A4PPIANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080275053-A1 | Selective modulators of prostaglandin E2 at EP1 receptors; analgesics, antiinflammatory agents; neurodegenerative diseases, bone or renal disorders; 3-{1-[2-(benzyloxy)-phenyl]-5-methyl-1H-pyrrol-2-yl}-benzoic acid | GLAXOSMITHKLINE | 2008-11-06 | — | — | US | disclosed |
| US-20080275053-A1 | Selective modulators of prostaglandin E2 at EP1 receptors; analgesics, antiinflammatory agents; neurodegenerative diseases, bone or renal disorders; 3-{1-[2-(benzyloxy)-phenyl]-5-methyl-1H-pyrrol-2-yl}-benzoic acid | GLAXOSMITHKLINE | 2008-11-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080275053-A1 | Selective modulators of prostaglandin E2 at EP1 receptors; analgesics, antiinflammatory agents; neurodegenerative diseases, bone or renal disorders; 3-{1-[2-(benzyloxy)-phenyl]-5-methyl-1H-pyrrol-2-yl}-benzoic acid | PTGER1, PTGER2, PTGDR | PTGER1 1/4885CYP2C9 820/4885CYP3A4 1749/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.